Safety and Immunogenicity of the Convacell® Recombinant N Protein COVID-19 Vaccine
Description
We have developed Convacell^(®)-a COVID-19 vaccine based on the recombinant nucleocapsid (N) protein of SARS-CoV-2. This paper details Convacell's^(®) combined phase I/II and IIb randomized, double-blind, interventional clinical trials. The primary
